Accelerating drug development for Alzheimer's disease through the use of data standards

Abstract Introduction The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. D...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Alzheimer's & dementia : translational research & clinical interventions 2017-06, Vol.3 (2), p.273-283
Hauptverfasser:	Neville, Jon, Kopko, Steve, Romero, Klaus, Corrigan, Brian, Stafford, Bob, LeRoy, Elizabeth, Broadbent, Steve, Cisneroz, Martin, Wilson, Ethan, Reiman, Eric, Vanderstichele, Hugo, Arnerić, Stephen P, Stephenson, Diane
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers CDISC Clinical outcome assessments Clinical trials Data science Data standards Drug development and Alzheimer's disease Mild cognitive impairment Neurology Other Regulatory science Therapeutic Area User Guide Translational science
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!